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Abstract: The theoretical prediction of drug-decorated nanoparticles (DDNPs) has become a very
important task in medical applications. For the current paper, Perturbation Theory Machine Learning
(PTML) models were built to predict the probability of different pairs of drugs and nanoparticles
creating DDNP complexes with anti-glioblastoma activity. PTML models use the perturbations of
molecular descriptors of drugs and nanoparticles as inputs in experimental conditions. The raw
dataset was obtained by mixing the nanoparticle experimental data with drug assays from the
ChEMBL database. Ten types of machine learning methods have been tested. Only 41 features
have been selected for 855,129 drug-nanoparticle complexes. The best model was obtained with the
Bagging classifier, an ensemble meta-estimator based on 20 decision trees, with an area under the
receiver operating characteristic curve (AUROC) of 0.96, and an accuracy of 87% (test subset). This
model could be useful for the virtual screening of nanoparticle-drug complexes in glioblastoma. All
the calculations can be reproduced with the datasets and python scripts, which are freely available as
a GitHub repository from authors.
Keywords: decorated nanoparticles; drug delivery; anti-glioblastoma; big data; perturbation theory;
machine learning; ChEMBL database
1. Introduction
Drug-decorated nanoparticles (DDNPs) have many medical applications, such as
drug delivery systems for different types of chemical compounds [1,2]. These systems
make it possible to study different combinations of drugs and nanoparticles designed to
treat specific medical conditions. Nevertheless, due to the huge number of combinations,
testing in a wet lab is not possible. Moreover, the synthesis of nanoparticles is expensive
and time consuming, whereby computational models are useful for predicting the possible
forming of effective drug-nanoparticle pairs.
According to the World Health Organization, glioblastoma multiforme (GBM) is the
most common and one of the most malignant central nervous system tumors. Treatment
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of this cancer is still being studied due to GBM’s location in the intracranial space and
the presence of the blood-brain barrier, which has particularly selective permeability to
some drugs. Current treatment involves surgical intervention and the application of
temozolomide and radiation, and it only guarantees a median survival of 15 months.
As a result of the high invasiveness of this treatment, some research has focused on
nanotechnology, which seems to be the best candidate for treating this disease, while
avoiding the inconveniences of the current procedure. Some nanomaterials have been
proven to pass through the blood-brain barrier and remain in GBM tissues; they could be
used to co-deliver a wide variety of antitumor drugs [3,4].
In order to mix nanotechnology, chemistry, and data analysis, the PTML method was
proposed by combining Perturbation Theory (PT) with Machine Learning (ML) [5–16].
Thus, different PT operators can be used to mix the original molecular descriptors with
the experimental conditions in order to predict biological activity. Some PT operators are a
generalization of chemoinformatics [17].
This paper mixes the perturbations of molecular descriptors of nanoparticle-drug
pairs into a classifier to predict the probability of nanoparticle-drug complexes having
anti-glioblastoma activity. Molecular properties, such as Polar Surface Area (PSA) and
logarithmic term (logP) of the octanol/water partition coefficient (P) [18], are used as
original descriptors for drugs. The logP values, such as ALogP, were calculated by ap-
proximation [19,20]. In the traditional model, the changes of the chemical structures are
characterized by molecular descriptors without taking into account the variation of drug
activity under different experimental conditions. Our model includes these variations of
the original molecular descriptors under different experimental conditions (perturbations).
Our dataset for drugs and nanoparticles was extracted from the ChEMBL database [21–27]
and from the literature. Using the same methodology, in previous publications, we have
demonstrated a similar nanoparticle-drug model against malaria [28]. The scope of this
paper is to provide a free, fast, and inexpensive computational method for predicting drug-
decorated nanoparticle delivery systems against glioblastoma. The model could be used to
screen in silica a considerable number of possible combinations of new compounds with
current or new nanoparticles (the first step in drug development). The same methodology
could be extended to other specific uses of nanocarriers in different scientific fields.
2. Results
New PTML classification models have been constructed to predict the probability
class for a nanoparticle-drug complex to have anti-glioblastoma activity. The results
are important for future nanomedicine applications. The dataset for these models used
mixed data from the ChEMBL database for drugs and literature sources for nanoparticles,
including experimental information from pharmacological assays. Perturbation Theory
(PT) was used to consider that the variation of drug-nanoparticle complexes depends on
perturbations of both nanoparticle and drug properties in specific experimental conditions.
Thus, the PTML models are complex functions that depend on experimental descriptors of
drugs and nanoparticles as opposed to the original molecular descriptors and the mean
values used in specific experimental conditions. Consequently, the models start with
a probability in the dataset for each drug-nanoparticle pair and add perturbations of
molecular descriptors for drugs and nanoparticles in specific experimental conditions by
using moving average (MA) functions from Box-Jenkins models [29,30].
The ML methods with default parameters (for extra information, please see the
GitHub repository: https://github.com/muntisa/nano-drugs-for-glioblastoma (accessed
on 21 October 2021)) have generated the baseline results presented in Table 1: accuracy
(ACC); area under the receiver operating characteristic curve (AUROC); precision; recall;
and f1-score (using single random split of data). The best model was selected by using the
AUROC and ACC metrics. Thus, the Bagging classifier is able to provide an AUROC of
0.9475 and ACC of 0.8657.
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Table 1. Baseline classification models for drug-decorated nanoparticle delivery systems against glioblastoma. (We included
bold letters to help readers to locate the best values).
Method ACC AUROC Precision Recall f1-Score
KNeighborsClassifier 0.7093 0.7882 0.7121 0.7093 0.7105
GaussianNB 0.6553 0.6752 0.6203 0.6553 0.5968
LinearDiscriminantAnalysis 0.7266 0.7988 0.7220 0.7266 0.7236
LogisticRegression 0.7206 0.8002 0.7150 0.7206 0.7169
DecisionTreeClassifier 0.8586 0.8544 0.8576 0.8586 0.8580
RandomForestClassifier 0.7923 0.8714 0.7943 0.7923 0.7931
XGBClassifier 0.7574 0.8502 0.7566 0.7574 0.7570
GradientBoostingClassifier 0.7599 0.8526 0.7603 0.7599 0.7601
BaggingClassifier 0.8657 0.9475 0.8655 0.8657 0.8656
AdaBoostClassifier 0.7175 0.8100 0.7100 0.7175 0.7119
In order to improve the best baseline model, a parameter search was used. Firstly, the
max_sample parameter of the Bagging classifier was tested for values from 0.1 to 1.0. The
best metrics were obtained for max_sample = 0.5 (see Figure 1). Secondly, this parameter
was maintained constant, and the number of decision trees was between 1 and 100 (see
Figure 2). AUROC and ACC did not improve significatively from 20 to 40 trees (by doubling
the number of trees) and, therefore, 20 trees was chosen as the optimal parameter. Thus,
the best model for predicting nanoparticle-drug pairs with anti-glioblastoma activity was
represented by the Bagging classifier with n_estimators = 20 trees and max_sample = 0.5.
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3. Discussion
In the next step, we studied the importance of the model features in order to un-
derstand what information is important for predicting nanoparticle-drug pairs with anti-
glioblastoma activity. Thirty of the most important features for the best classifier (normal-
ized values) are presented in Figure 3. It can be seen that both descriptors for drugs and
nanoparticles are important for the classification.
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The variation of PSA for drugs in different types of cells (c1) is the most important
feature for this classifier, d_DPSA(c1). The polarity of the drug surface seems to be the most
important feature because it is linked to the membrane solubility of the drugs. In addition,
it appears that the variation of molecular descriptors for drugs and nanoparticles with the
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type of cells (c1) is important (see the first and most important features in Figure 3). For
drugs, the perturbation of PSA seems to be more important than ALOG in different cells
(c1) and organisms (c2). For nanoparticles, the most important features are (1) variations
of the surface area of acceptor atoms (SAccoat); (2) np large (L) and average atomic
Van der Waals volume of all atoms in the np (V) with the parameter np assay—c0(np);
(3) the cell line np assay—c1(np); (4) the np shape—c2(np); and (5) np medium—c3(np)
(e.g.,: np_DSAaccoat(c0), np_DLnp(c1), np_DVnpu(c1)). The most important feature
for drugs was double the importance of this model compared with the most important
feature for nanoparticles. Thus, the best model obtained with all features showed the
experimental importance of polarity for both drugs and nanoparticles as well as the volume
of nanoparticles. This analysis of feature importance is in line with the general knowledge
about drug and nanoparticle properties, especially for the blood-brain barrier.
Generally, in Machine Learning models, the least important features could add noise
to the data, decreasing model performance. Therefore, we eliminated the less important
features to see the course of the model’s accuracy (ACC). From the initial 104 features, we
chose to eliminate 64 less important features (see Figure 4). The final model was based
on only 41 features of nanoparticles and drugs: probability; d_DPSA(c0); d_DALOGP(c0);
d_DPSA(c1); d_DALOG(c1); d_DPSA(c2); d_DALOGP(c2); d_DPSA(c3); d_DALOGP(c3);
d_DPSA(c4); d_DALOGP(c4); d_DPSA(c5); d_DALOGP(c5); d_DPSA(c6); d_DALOGP(c6);
d_DPSA(c7); d_DALOGP(c7); d_DPSA(c8); d_DALOGP(c8); np_DNMUnp(c0); np_
DLnp(c0); np_DVnpu(c0); np_DPnpu(c0); np_DAMRcoat(c0); np_DSAtotcoat(c0); np_
DSAacccoat(c0); np_DNMUnp(c1); np_DLnp(c1); np_DVnpu(c1); np_DPnpu(c1); np_
DNMUnp(c2); np_DLnp(c2); np_DVnpu(c2); np_DPnpu(c2); np_DSAtotcoat(c2); np_DLnp
(c3); np_DVnpu(c3); np_DPnpu(c3); np_DLnp(c5); np_DVnpu(c5); and np_DPnpu(c5).
The final model is characterized by ACC = 0.8712, AUROC = 0.9602, precision = 0.8716,
recall = 0.8712, and f1-score = 0.8714. This model can be used for future in silica screening
for drug-nanoparticle pairs.
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In conclusion, we demonstrated that mixing original descriptors for drugs and
nanoparticles with the experimental conditions allowed us to obtain perturbations of
molecular descriptors under specific conditions as inputs for classification models for
the prediction of anti-glioblastoma drug-decorated nanoparticle delivery systems. The
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methodology tested different Machine Learning methodologies with the default param-
eters, improved the parameters for the best method, and reduced the number of input
features using a feature selection method based on feature importance.
4. Materials and Methods
The proposed methodology for building classifiers for the prediction of DDNPs is
based on the perturbation of molecular descriptors in specific experimental conditions
(see Figure 5): (1) Raw dataset design using nanoparticle experimental properties and
anti-glioblastoma drugs from the literature and public databases; (2) Feature engineering
by mixing drug assay experimental data with nanoparticle and drug molecular descriptors,
resulting in experimental-centered transformation of the original descriptors with the
help of the Box-Jenkins moving average operators; (3) Model dataset design by using the
new descriptors for pairs of nanoparticles and drugs; (4) Dataset preprocessing (cleaning,
standardization, elimination of low variance features); (5) Building of baseline models with
ten machine learning methods, using default parameters; (6) Parameter optimization for
the best model; (7) Feature selection by eliminating the less important features to obtain
the final classification model.
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In the case of the drugs, after filtering the dataset, three types of biological activities
were considered (vij): EC50, IC50, and LC50. EC50 represents the drug concentration
that gives a half-maximal response. IC50 is the concentration of an inhibitor where the
response (or binding) is reduced by half. LC50 represents the compound concentration
that is lethal for 50% of the population exposed. The natural logarithm was used to
transform these values, log(vij). A cutoff value of 10 was used for all activities (close to the
mean values). For the nanoparticles, five activities were used as natural logarithm: CC50,
EC50, IC50, LC50, and TC50. CC50 represents the 50% cytotoxic concentration defined
as the compound concentration that reduced cell viability by 50%, and TC50 defines the
compound concentration required to obtain no more than a perceptible effect on 50% of the
exposed population of cells. The transformation of these values in a class used a cutoff = 6.
All the calculations can be reproduced with the scripts included in our GitHub repository.
Different experimental conditions have been used for:
- Drugs (d): c0 = Biological activity; c1 = cell name, c2 = organism, c3 = target type,
c4 = assay organism, c5 = target mapping, c6 = level of confidence, c7 = type of curation,
and c8 = assay type;
- Nanoparticles (np): c0(np) = Parameter np assay, c1(np) = Cell line np assay, c2(np) = np
shape, c3(np) = np medium, c4(np) = np assay time, c5(np) = surface coating.
Additional information about the mean values used to calculate the final features is
presented as Supplementary Materials (SM1-ExperimentalCondition_Means.xlsx).
The original molecular descriptors are different for drugs and nanoparticles:
- For drugs: PSA and ALOGP;
- For nanoparticles: NMUnp, Lnp, Vnpu, Enpu, Pnpu, Uccoat, Uicoat, Hycoat, AMR-
coat, TPSA(NO)coat, TPSA(Tot)coat, ALOGPcoat, ALOGP2coat, SAtotcoat, SAacccoat,
SAdoncoat, Vxcoat, Vvdw, MGcoat, Vvdw, ZAZcoat, PDIcoat.
np = nanoparticle; npu = nanoparticle elemental unit (Al, SiO2, etc.); NMU = number
of monomeric units in the np; V = <V(cm3/mol)> = average of atomic Van der Waal vol-
ume for all atoms in the npu; E = electronegativity; P(A3) = atomic polarizability; L = np
large (experimental data); null = not applicable or not available; UC = uncoated nanopar-
ticles; NMU = number of monomer units; HMT = hexamethylenetetramine; TMAOH
= tetramethylammonium hydroxide; DMEM = Dulbecco’s modified Eagle’s medium;
coat = np coating; Uc = unsaturation count; Ui = unsaturation index; Hy = hydrophilic fac-
tor; AMR = Ghose-Crippen molar refractivity; TPSA(NO) = topological polar surface area
using N, O polar contributions; TPSA(Tot) = topological polar surface area using N, O, S, P
polar contributions; ALOGP2 = squared Ghose-Crippen octanol/water partition coefficient
(logP2); SAtot = total surface area from P_VSA-like descriptors; SAacc = surface area of
acceptor atoms from P_VSA-like descriptors; SAdon = surface area of donor atoms from
P_VSA-like descriptors; Vx = McGowan volume; VvdwMG = van der Waals volume from
McGowan volume; VvdwZAZ = van der Waals volume from Zhao-Abraham-Zissimos
equation; PDI = packing density index.
The final features, such as experimental descriptors, DXj(ci), were obtained by the
difference (D) between the original descriptor (Xj) and the mean of the descriptor under
specific experimental conditions (ci): DXj(ci) = Xj—mean(X)ci. The name of the model
features will have the format [d_/np_] [original descriptor name]([experimental condition]).
For example:
- d_DPSA(c1) = difference (D) between original values of PSA descriptor and the mean
of PSA values in experimental condition c1 (for drugs, d_);
- np_DLnp(c5) = difference between original L value and the mean of L values in
experimental condition c5 (for nanoparticles, np_/np).
An extra input feature (probability) was created as the probability of c0 for drug-NP
pairs (count of the number of drug-NP pairs for each c0 activity type/total number of pairs).
The final output variable (Class) was calculated using drug and nanoparticle desirability
depending on the biological activity:
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- For drugs: priori desirability was −1 for EC50 and IC50, and 1 for LC50;
- For NPs: priori desirability was −1 EC50 and IC50, and 1 for CC50, LC50, TC50.
New temporal columns have been created for the Good/Bad classes for drugs and
NPs: ‘Good’ if desirability = 1 and log(vij) > cutoff or desirability = −1 and log(vij) < cutoff;
‘Bad’ if desirability = 1 and log(vij) < cutoff or desirability = −1 and log(vij) > cutoff. The
final output variable (Class) has a value of 1 if both columns for drug and NP are ‘Good’
(otherwise, it has a value of 0). The initial dataset with drug-NP pairs has 855,129 instances
and 119 input features. The input feature values were standardized. All the scripts for
obtaining the final dataset and the raw datasets can be found in the GitHub repository:
https://github.com/muntisa/nano-drugs-for-glioblastoma (accessed on 21 October 2021).
The raw datasets with drug and nanoparticle descriptors and other descriptions from public
datasets and the literature can be downloaded from the same repository. Thus, the raw drug
descriptors from drug(neuro).csv as datasets/drug(neuro).zip and the raw nanoparticle
descriptors from nano(neuro).csv as nano(neuro).zip have been combined to create drug-
nanoparticle pairs of descriptors using the script 0-CreateDatasetWithPairs.ipynb.
Ten Machine Learning scikit-learn classifiers were tested to find the best classifier for
the prediction of the desirability of nanodrug carriers in glioblastoma:
1. KNeighborsClassifier = KNN—k-nearest neighbors: It is one of the most popular
non-parametric classifiers available. It works by assigning an unclassified sample to
the same class as the nearest k samples found in the training set [31].
2. GaussianNB = Gaussian Naive Bayes: It is a simple classification algorithm that is
based on Bayes’ theorem, which describes the probability of an event based on prior
knowledge of conditions related to said event. It is the simplest and the most popular
of all similar classifiers [32].
3. LinearDiscriminantAnalysis = LDA—linear discriminant analysis [33]: It is a super-
vised statistical method based on the projection of data to a lower dimension. The
objective is to maximize the scatter between classes versus the scatter within each
class. Thanks to this projection, the task of separating the data should be made easier.
4. LogisticRegression = LR—Logistic regression [34]: It is a linear model with the capac-
ity to estimate the probability of a binary response using different factors.
5. DecisionTreeClassifier = DT—Decision Tree (DT): It a classifier that builds a series
of models in the form of a tree structure. Then, it infers its decision rules from
the features of said trees. Thus, the paths from root to leaf represent classification
rules [35].
6. RandomForestClassifier = RF—Random forest [36]: It consists of a large number
of individual decision trees that work as an ensemble. Each individual tree in the
random forest makes a prediction, and then, the class with the largest amount of votes
is chosen as the model’s prediction. Each tree is generated using a bootstrap sample
drawn randomly from the original dataset using a classification or regression tree
(CART) method and the Decrease Gini Impurity (DGI) as the splitting criterion [36].
RF is mainly characterized by low bias, low correlation between individual trees, and
high variance.
7. XGBClassifier = XGB—XGBoost: It is a tree-based ensemble method in which weak
classifiers are added in order to correct errors (sequential trees [37]). It should be
noted that this classifier demonstrates an excellent performance through the Kaggle
competition projects [38].
8. GradientBoostingClassifier = Gradient Boosting for classification—GB classifier: Gra-
dient Boosting is a technique that produces a prediction based on an ensemble of
weak prediction models (in general, decision trees) [39].
9. BaggingClassifier = Bagging classifier: Similarly to a GB classifier, a Bagging classifier
is an ensemble meta-estimator, meaning that it uses as a basis a number of weaker
prediction models in order to make its own prediction. It fits each base classifier
on a random subset of the original dataset and then aggregates all the individual
performances in order to form a final prediction [36].
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10. AdaBoostClassifier = AdaBoost classifier: In a similar fashion to the two previous
examples, an AdaBoost classifier is a meta-estimator that first fits a classifier on the
original dataset and, subsequently, fits a series of copies of said classifier on the same
dataset but adjusting the weights of incorrectly classified instances, meaning that the
following classifiers will focus on the most difficult cases [36].
The entire processing of the dataset and ML was done using scikit-learn from python
in Jupyter notebooks (see GitHub repository). In the first step, the initial dataset was
divided into 75% training and 25% test subsets (using stratification = maintain the same
ratio of positive and negative classes in each subset). Thus, the training/test subsets have
641,346/213,783 instances. Based on the training subset, the initial number of features of
119 was lowered to 104 by removing the features with a variance of less than 0.0001. The
following features were removed: np_DVxcoat(c5), np_DPDIcoat(c5), np_DHycoat(c5),
np_DTPSA(Tot)coat(c5), np_DAMRcoat(c5), np_DSAacccoat(c5), np_DALOGP2coat(c5),
np_DUccoat(c5), np_DVvdwMGcoat(c5), np_DSAdoncoat(c5), np_DUicoat(c5), np_DVvdw
ZAZcoat(c5), np_DALOGPcoat(c5), and np_DSAtotcoat(c5). These are nanoparticle de-
scriptors for experimental condition c5. The featured data for the resulting subsets were
standardized in order to speed up future ML methods.
A baseline calculation was done using ten ML methods: KNN, GaussianNB, LDA,
LR, DT, RF (100 estimators), XGB (100 estimators), GB, Bagging, and AdaBoost. The
calculated metrics were accuracy (ACC), area under the receiver operating characteristics
curve (AUROC) [40,41], precision, recall, and f1-score [42]—script 1_CreateDataSets_
BaselineML.ipynb.
With the best ML method from the baseline results, new improvements have been
made by using a search grid for the best hyperparameters of the best classifier (number of
decision trees and number of instances to use in each tree)—scripts 2-Grid Search.ipynb,
2-Grid Search2.ipynb, and 2-Grid Search3.ipynb. In the next step, a feature selection was
applied to reduce the number of features by using the feature importance for the best
classifier (3-BestModel.ipynb). In the case of the ensemble methods using decision trees,
the feature importance was calculated as the mean of feature importance in all decision
trees (sklearn function). The feature importance values were normalized to values between
1 and 0 and only features with importance greater than 10% were maintained into the final
dataset with the best classifier.
5. Conclusions
The current PTML models combine drug and nanoparticle descriptors with the ex-
perimental conditions into the perturbation of molecular descriptors for the prediction of
anti-glioblastoma nanodrug carriers. The best classification model is based on 41 selected
features for 855,129 drug-nanoparticle complexes, a Bagging classifier with 20 decision
trees, AUROC of 0.96, and accuracy of 87%. The model could be used to virtually screen
a huge number of possible nanoparticle-drug complexes for anti-glioblastoma activity.
This could be useful in further studies in search of a less invasive treatment for this dis-
ease. All the calculations can be reproduced using the GitHub repository available at
https://github.com/muntisa/nano-drugs-for-glioblastoma (accessed on 21 October 2021).
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